We read with great interest the article "The need for secondlook endoscopy to prevent delayed bleeding after endoscopic submucosal dissection for gastric neoplasms: a prospective randomized trial" by Kim et al. 1 The study was designed to evaluate whether the second-look endoscopy (SLE) strategy can reduce the delayed bleeding complication in patients who underwent endoscopic submucosal dissection (ESD) for gastric neoplasms.
, low platelet count, and use of antithrombotic drugs 2 are proposed risk factors for the delayed bleeding following ESD, but the significance of these factors varies among investigators. What can we do to reduce the delayed bleeding following ESD? The visible vessels are apt to be injured. Takizawa et al. 5 proved the usefulness of the post-ESD coagulation (PEC) of visible vessels on the ESD ulcer base. The delayed bleeding was more frequent in non-PEC group than PEC group, the odds ratio 2.47 (95% confidence interval, 1.27 to 4.80). Second consideration is about the SLE. The SLE can evaluate the healing condition of the ulcers and do additional hemostasis if necessary. However, there are argues about the cost and benefit of the SLE on peptic ulcers as well as the ESD ulcers.
With introduction of proton pump inhibitor (PPI), the morbidity and mortality of peptic ulcer disease has markedly decreased. Consequently, the role of routine SLE for peptic ulcer has also been on the table of debate. A meta-analysis by El Ouali et al. 8 reported the value of the SLE following bleeding peptic ulcer. The rebleeding rate and the need of surgery decreased to a half, but mortality was not influenced by SLE. Among the analyzed literatures, a trial using high-dose PPI did not show a benefit of SLE. When removing the two trials including patients at highest risk of rebleeding, no significant benefit attributable to SLE was noted. Another report by Imperiale and Kong 9 suggested that, if rebleeding risk is not 31% or greater, routine SLE cost highly over the benefit for bleeding peptic ulcer. Studies of SLE on the ESD ulcer look more unfavorable (Table  2) .
1,10-12 Goto et al. 10 reported an interesting observation that a half of patients who experienced the delayed bleeding presented after SLE and bleeding risk stigmata were not recognized on SLE. Two randomized controlled studies failed to prove beneficial effect of SLE in terms of the delayed bleeding prevention. 11 Ryu et al. 11 reported 16.2% of the delayed bleeding in the SLE group and 11.1% in non-SLE group (p=0.66). None of the supposed factors was found to be related to the delayed bleeding. This article by Kim et al. 1 also concluded no benefit of SLE.
Now can we safely conclude that the SLE is not needed any more in ESD ulcer? The facts lies on that the delayed bleeding is not zero and we still have to use SLE in other way of a better cost-benefit aspect. Factors including large ulcer and old age are obscure in significance. It is unclear that SLE has benefit in patients with these factors. Kim et al. 1 suggested that the large tumor (>2.0 cm) is a risk factor with odds ratio of 4.47. But it is weird that they did not compare the actual size of tumor with t-test rather than to compare the proportion of the over 2.0 cm tumors with chi-square test. It is highly suspicious that authors failed to prove the significance with tumor size as delayed bleeding risk factor and they may devise a new parameter. If this suspicion is correct, we have no evidence that any factor exerts effect on the delayed bleeding in SLE study. 1, 11 The Forrest classification is the most powerful predictor for rebleeding in ulcer disease. 13 On ESD ulcers, a prospective observational investigation reported that the rebleeding rate was 8.6% in patients with high risk stigma and 0.8% with low risk stigma on SLE. 12 Choi et al. 12 gave valuable cues suggesting high risk stigmata on SLE. Nausea and the presence of submucosal fibrosis during ESD increased the odds ratios of high risk stigmata to 4.76 and 3.91, respectively. Evidences tell that the routine SLE has a limited role on the prevention of the delayed bleeding, especially for ESD ulcer. The question should be changed. Not "Do we need the SLE following ESD routinely?" but "Which patient should we do SLE following ESD?" We need to find the proper indication for SLE following ESD. New trials will compare the selective SLE and non-SLE strategies. Criteria for selection may consists of large mucosal defect, longer procedure, old aged patients, high grade histology, use of antithrombotic drugs, presence of submucosal fibrosis during ESD and nausea symptom.
